Medical and Biotech

• Your science is genuinely differentiated but the content that represents it is not: The clinical evidence, the mechanism of action, the manufacturing precision, and the patient outcomes that distinguish your product from every competing approach are invisible in a data sheet and a peer-reviewed abstract. The content that should make those differentiators visible to clinicians, procurement committees, and investors — clinical education video, product demonstration, mechanism of action animation — either does not exist, was produced once and is now outdated, or does not meet the production standard the audience expects from an organisation claiming to operate at the level you claim.‍
• Clinical and commercial communications operate on separate tracks with no shared infrastructure: The medical affairs team is producing KOL content. The commercial team is producing sales enablement video. The marketing team is producing brand content. The investor relations team is producing programme updates. Each track has its own vendor, its own brief, its own visual standard, and its own approval process — producing a library of content that does not cohere into a unified organisational communications strategy and does not compound in the way a systematic program would.‍
• Regulatory and compliance review creates unpredictable production timelines: Every piece of external content requires medical, legal, and regulatory review before it can be published. Most production workflows were not built with the compliance review process integrated from the start — which means compliance review is retrofitted at the end of the production process, creating the bottlenecks, the revision cycles, and the timeline failures that make video production feel more expensive and more painful than it should be.‍
• Investor communications are produced reactively and the quality reflects it: Program milestone announcements, data readout communications, conference presentations, and investor day content are produced individually — each one a separate coordination effort under deadline pressure, with no documented production standard, no consistent visual treatment, and no content library to draw from. The communications that should be building investor confidence and analyst credibility are instead demonstrating the absence of a systematic communications infrastructure.‍
• Clinical education content is not keeping pace with the clinical evidence: The clinical evidence base for your product is growing — new data, new indications, new patient populations, new real-world outcomes. The clinical education content that should communicate that evidence to the prescribing clinicians and procurement committees who need it is not keeping pace — because there is no documented workflow for translating new evidence into new educational video content on a consistent timeline.‍
• The mechanism of action is the most compelling thing about the product and most audiences cannot visualize it: The molecular interaction, the cellular mechanism, the device function, or the biological pathway that makes your product work — and that makes it genuinely different from every existing approach — cannot be filmed. It can be animated. And for most medical and biotech products, the animation that makes the mechanism visible to a clinician, an investor, or a patient is the single highest-value video asset the organisation can produce. Most organisations produce it once, in a format that quickly becomes outdated, without a documented process for keeping it current.

Medical and biotech companies operate at the intersection of the highest scientific complexity and the highest-stakes audience decisions in any industry. The clinician deciding whether to prescribe, the investor deciding whether to fund, the regulator deciding whether to approve, the patient deciding whether to consent, and the payer deciding whether to reimburse — all of these audiences are making consequential decisions based on the quality, the clarity, and the credibility of the information they receive.

Video is the format that communicates complex medical and scientific information most effectively to these audiences — because it combines the visual evidence of mechanism, data, and outcome with the human credibility of the clinical investigators, company leaders, and patient advocates who can speak to the science from genuine expertise and lived experience.

A mechanism of action animation that shows a molecular interaction at the cellular level communicates something that no written description can replicate — the visual logic of why the science works, presented in a format that a clinician can follow, an investor can reference, and a patient can understand at the appropriate level of abstraction for their context.

A KOL video that shows a respected clinical investigator explaining the patient selection criteria for a new therapy communicates the clinical credibility of the evidence in a format that is more persuasive to a prescribing clinician than the same information presented in a data table — because the clinician is not just evaluating the data, they are evaluating the clinical judgment of a peer who has applied that data in a real patient population.

A patient story video that shows a real patient describing the experience of treatment and the specific change in their quality of life communicates the human impact of the science in a format that no efficacy endpoint can replicate — because the patient outcome is the ultimate measure of whether the science matters, and video is the format that makes that outcome real to every audience that needs to be moved by it.

The medical and biotech organizations that communicate most effectively are not necessarily the ones with the most compelling science. They are the ones whose science is most clearly, most credibly, and most systematically communicated — to every audience that needs to understand it, at every stage of the development and commercialization process, in the format that makes the science accessible without sacrificing the accuracy and the rigor that the medical community demands.

Start here if you're not ready for Install.

For marketing teams with one specific need right now, these services are available as standalone engagements with defined scope and clear deliverables.

Need a larger or more complex project? We provide custom quotes for enterprise-level video projects and campaigns. Stack more than two services and you're almost certainly better served by VidOS Install.

VID's medical and biotech clients share a specific profile. They are established organisations — commercial-stage medical device companies, clinical-stage biotech firms, healthcare technology platforms, and diagnostic companies — with genuine scientific or clinical differentiation and a communications challenge that their current content operation is not fully solving.

You are the right fit if:

• You are a commercial-stage or late clinical-stage medical device, pharmaceutical, or biotech company whose clinical and commercial communications need to communicate complex science clearly and compliantly to multiple audiences simultaneously
• You are a healthcare technology company — digital health platform, clinical decision support, remote patient monitoring — whose product requires video demonstration and whose current product content does not match the sophistication of the technology it represents
• You are a diagnostic company — molecular diagnostics, imaging, point-of-care — whose clinical utility needs to be communicated to ordering clinicians, procurement committees, and laboratory directors in a format that static sales materials cannot achieve
• You are a life sciences company preparing for a major inflection point — a pivotal data readout, a regulatory submission, a commercial launch, or an investor day — whose communications infrastructure needs to be ready before the moment rather than assembled in its aftermath
• You are a biotech or medical device company whose mechanism of action animation is outdated, whose clinical education content is not keeping pace with the evidence, or whose investor communications are produced reactively rather than systematically
• You are a commercial medical device or pharmaceutical company whose sales enablement content is not consistently reaching every rep in every territory at the standard the product and the evidence require